Allogene Therapeutics, Inc.
(NASDAQ : ALLO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
ARRYArray BioPharma Inc.
0.01%46.438.1%$738.67m
AMGNAmgen Inc.
0.36%176.751.3%$505.40m
CELGCelgene Corporation
0.04%91.801.3%$444.39m
GILDGilead Sciences, Inc.
-1.71%66.910.9%$404.46m
BIIBBiogen Inc.
-0.34%232.821.3%$386.34m
ILMNIllumina, Inc.
0.31%303.233.5%$336.82m
REGNRegeneron Pharmaceuticals, Inc.
-0.09%297.942.6%$277.91m
SRPTSarepta Therapeutics, Inc.
-2.25%153.3814.7%$204.17m
ALXNAlexion Pharmaceuticals, Inc.
0.66%123.852.0%$199.45m
VRTXVertex Pharmaceuticals Incorporated
0.14%176.611.9%$187.74m
EXASExact Sciences Corporation
-0.87%115.1824.1%$139.27m
AAgilent Technologies, Inc.
-0.85%69.951.6%$134.12m
INCYIncyte Corporation
-1.61%80.082.5%$114.23m
BLUEBluebird Bio, Inc.
-1.27%134.0314.3%$97.95m
BMRNBioMarin Pharmaceutical Inc.
-2.13%82.204.3%$87.46m

Company Profile

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam on November 2017 and is headquartered in South San Francisco, CA.